Module 1: Introduction to Pharmacovigilance

• Overview of pharmacovigilance and its significance in drug safety 

• History and evolution of pharmacovigilance systems 

• Key terminologies and concepts in pharmacovigilance 

• Role of pharmacovigilance in public health and regulatory compliance 

• Global pharmacovigilance landscape and key stakeholders 

Module 2: Regulatory Framework and Guidelines

• Overview of regulatory agencies (FDA, EMA, WHO, ICH) 

• Good Pharmacovigilance Practices (GVP) and guidelines 

• Understanding the International Conference on Harmonisation (ICH) E2E guidelines 

• Compliance with local and international pharmacovigilance regulations 

• Reporting requirements for adverse events and safety data 

Module 3: Adverse Drug Reactions (ADRs) and Reporting

• Types of adverse drug reactions and their classifications 

• Mechanisms of ADRs: pharmacological vs. non-pharmacological 

• Importance of spontaneous reporting and signal detection 

• Developing and managing adverse event reporting systems 

• Roles and responsibilities of healthcare professionals in ADR reporting 

Module 4: Data Collection and Management

• Methods for collecting safety data: spontaneous reports, clinical trials, and registries 

• Use of databases and electronic systems for pharmacovigilance (e.g., Oracle Argus, VigiBase) 

• Data standardization and coding (MedDRA, WHO-ART) 

• Ensuring data quality and integrity in pharmacovigilance systems 

• Managing data privacy and confidentiality in safety reporting 

Module 5: Signal Detection and Risk Assessment 

• Definition and importance of signal detection in pharmacovigilance 

• Statistical methods for signal detection and data mining techniques 

• Risk assessment methodologies: qualitative and quantitative approaches 

• Evaluating benefit-risk balance of medications 

• Implementing risk management plans (RMPs) and risk minimization strategies 

Module 6: Post-Marketing Surveillance

• Importance of post-marketing surveillance in drug safety monitoring 

• Overview of Phase IV studies and their role in pharmacovigilance 

• Conducting risk communication and management post-approval 

• Monitoring long-term safety and efficacy of marketed drugs 

• Case studies of post-marketing surveillance and safety concerns 

Module 7: Pharmacovigilance in Special Populations

• Considerations for pharmacovigilance in pediatrics, geriatrics, and pregnant women 

• Challenges in safety monitoring for vulnerable populations 

• Reporting and managing ADRs in special populations 

• Ethical considerations in pharmacovigilance for specific groups 

• Designing studies to assess safety in diverse populations 

Module 8: Pharmacovigilance Audits and Inspections 

• Overview of auditing and inspection processes in pharmacovigilance 

• Preparing for regulatory inspections: documentation and compliance 

• Conducting internal audits of pharmacovigilance systems 

• Identifying and addressing non-compliance issues 

• Developing corrective and preventive action plans (CAPA) 

Module 9: Risk Communication and Safety Reporting

• Effective risk communication strategies in pharmacovigilance 

• Developing risk communication materials for healthcare providers and patients 

• Reporting safety information to regulatory authorities 

• Communicating with stakeholders during safety crises 

• Best practices for public health messaging and transparency 

Module 10: Emerging Trends and Technologies in Pharmacovigilance

• Impact of digital health and real-world evidence on pharmacovigilance 

• Utilizing Artificial Intelligence (AI) and machine learning for data analysis 

• The role of social media and patient-reported outcomes in safety monitoring 

• Innovations in pharmacovigilance reporting and database management 

• Future directions and challenges in the field of pharmacovigilance 

Module 11: Capstone Project: Case Study in Pharmacovigilance

• Conducting a case study on a real-world drug safety issue 

• Analyzing data, identifying signals, and making recommendations 

• Presenting findings and proposed actions to address safety concerns 

• Final project review with feedback from industry experts 

• Discussion of key lessons learned and best practices in pharmacovigilance